Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer

Sarat Chandarlapaty

ABSTRACT

Mutational activation of growth factor signaling pathways is commonly observed and often necessary for oncogenic transformation. Under physiologic conditions, these pathways are subject to tight regulation through negative feedback, which limits the extent and duration of signaling events after physiologic stimulation. Until recently, the role of these negative feedback pathways in oncogene-driven cancers has been poorly understood. In this review, I discuss the evidence for the existence and relevance of negative feedback pathways within oncogenic signaling networks, the selective advantages such feedback pathways may confer, and the effects such feedback might have on therapies aimed at inhibiting oncogenic signaling.

Significance: Negative feedback pathways are ubiquitous features of growth factor signaling networks. Because growth factor signaling networks play essential roles in the majority of cancers, their therapeutic targeting has become a major emphasis of clinical oncology. Drugs targeting these networks are predicted to inhibit the pathway but also to relieve the negative feedback. This loss of negative feedback can itself promote oncogenic signals and cancer cell survival. Drug-induced relief of feedback may be viewed as one of the major consequences of targeted therapy and a key contributor to therapeutic resistance. Cancer Discov; 2(4):311–9. ©2012 AACR.

INTRODUCTION

Biologic systems must maintain homeostasis in the face of various physiologic perturbations and environmental stresses. One of the main mechanisms used to enable homeostasis is “negative feedback.” Negative feedback may simply be thought of as a direct output of a given stimulus that serves to deactivate that stimulus. The role of negative feedback in generating stability in complex systems is observed at all levels of biologic organization: in ecosystems (e.g., predator–prey relationships), multisystem organ regulation (e.g., thyroid hormone production), and intracellular function (e.g., transcriptional regulation through operons). The regulation of growth factor signaling pathways by negative feedback is a universal mechanism for limiting the extent and duration of signaling output. The manifold roles of negative feedback loops on signaling systems in normal cell physiology and developmental biology have been well appreciated (1, 2). More recently, several studies have sought to determine the implications of feedback regulation of pathways that are driven by constitutively activated oncoproteins in tumor cells. In this review, I discuss the relevance of negative feedback pathways within oncogenic signaling networks, the selective advantages these pathways may confer, and the implications of feedback regulation for therapies aimed at inhibiting growth factor signaling.

SIGNAL ACTIVATION AND NEGATIVE FEEDBACK

The binding of epidermal growth factor (EGF) to the EGF receptor triggers a rapid succession of intermolecular binding and phosphorylation steps that induce and amplify the signal to ultimately drive process through cell cycle checkpoints, transcription factor activation of gene expression modules, assembly of macromolecules to promote protein translation, and alterations in choice of nutrient use programs (Fig. 1). On a time scale of minutes to hours, these signaling events also induce negative regulatory events. These events cause the signal to be self-limited and help specify its strength and duration (Fig. 1C). These negative regulatory loops are initiated as a direct consequence of EGF receptor (EGFR) activation. Several mechanisms for feedback regulation of the EGFR pathway have been identified: (i) the GRB2 adaptor protein recruits...
the CBL E3 ubiquitin ligase to mediate endocytosis and downregulation of EGFR; (ii) the extracellular signal-regulated kinase (ERK) 1/2 kinase phosphorylates upstream pathway components SOS and RAF at sites that promote their inactivation; (iii) the mitogen-activated protein kinase (MAPK) phosphatase that inhibits ERK1/2 function is transcriptionally upregulated in response to ERK1/2 activation; and (iv) activation of AKT and mTOR results in downregulation of cooperating receptor tyrosine kinases (RTK) like HER3 and IGF1R (3, 4). These represent only a fraction of the negative feedback events that limit the effects of growth factor stimulation.

**Theoretical Advantages of Negative Feedback**

The presence of negative feedback modules in signaling systems from yeast to drosophila to humans suggests that they confer selective advantages. Biochemical and computational methods have identified several possible mechanisms whereby regulation through negative feedback improves cellular fitness. One major consequence of feedback inhibition of growth factor signaling by negative feedback is that it increases the “robustness” of the system: preserving network stability in the face of environmental and genetic stress (5). This property was illustrated by an analysis of the effects of different feedback states on the response of the MAPK signaling pathway to growth factor (6). Yen-gar and colleagues compared a “low feedback state” (depressed MAPK phosphatase expression) and a “feedback present state” for ERK response to platelet-derived growth factor (PDGF) and found that the low feedback state exhibited a bistable response to growth factor. In this case, in the absence of PDGF, there was no ERK signaling, whereas ERK signaling was maximally stimulated over a wide range of PDGF concentrations ranging from low to high. By contrast, the “feedback present state” exhibited a proportional response with different amounts of growth factor inducing different levels of ERK activation. The experiments suggest that the presence of feedback could potentially provide advantages in terms of fitness and appropriate response relative to the condition of the environment. A related advantage of feedback regulation of signaling systems is that it allows diversification in signal response. Induction of negative feedback by morphogens such as Sonic Hedgehog plays a role in cell fate specification by enabling unique cellular responses to subtle differences in ligand concentration (7). As such, the presence of negative feedback can potentially allow the diversity necessary for multicellular structures and organs that may be selectively advantageous in less favorable environments. Finally, feedback inhibition plays an integral role in most signaling pathways because it serves to dampen and turn off the signal, thereby preventing potentially toxic overactivation of signaling output in response to growth factors or other stimuli. Moreover, in most complex systems, biologic and designed, it can prevent potentially toxic overactivation of signaling output in response to growth factors or other initiators of signaling. Moreover, in systems regulated by positive feedback loops, the presence of a negative feedback loop could prevent runaway activation in response to a signal.

While it is clear that negative feedback is a key component of normal cellular signaling pathways and provides selective advantages that ensure its preservation, the role of negative feedback in cancer cells is more complex. The unregulated proliferation of cancer cells is driven in many cases by constitutively activated oncoproteins that cause hyperactivation of growth factor signaling pathways. The selective advantages of feedback modules that can downregulate such signals are less obvious. Perhaps mutational events that attenuate negative feedback are a critical step of the process of transformation. On the other hand, loss of negative regulation with complete dysregulation of signaling output is likely to result in cell death. We may ask whether oncoproteins induce constitutive negative
feedback in cancer cells or whether these pathways are inactivated during carcinogenesis.

**Negative Feedback Is Associated with Oncogene-Induced Senescence**

Several common, oncogenic lesions in growth factor signaling pathways (e.g., mutant RAS or loss of PTEN) fail to fully transform normal cells. Oncogene-induced senescence is among the mechanisms that is thought serve as a safeguard against transformation (8). Studies by Courtois-Cox and colleagues (9) described constitutive activation of RAS signaling due to loss of the RAS-GAP NFI or overexpression of a constitutively active C-Raf allele leads to transient activation of AKT and ERK pathways. Activation of these pathways results in induction of the expression of several families of proteins [Sproutys, dual specificity phosphatases (DUSPs), and RAS-GAPs] that function in part by feedback inhibiting RAS signaling (9). Induction of their expression was associated with profound downregulation of AKT and ERK activity and stimulation of a senescence phenotype. Senescence was thought to be related to induction of the activity of the FOXO tumor suppressor in response to feedback inhibition of AKT and ERK signaling. Although these studies did not define the loss of the negative feedback as sufficient for ultimate transformation, they did describe a set of negative feedback responses that emerged from oncogene activation and associated their presence with tumor suppressive functions.

**EGFR Signaling Is Regulated by Negative Feedback**

The role of negative feedback in regulating the EGFR-ERK pathway was explored by Amit and colleagues (10). They studied EGFR-dependent induction of transcription in HeLa cells and demonstrated that EGF induces numerous negative feedback components including proteins that can downregulate ERK (e.g., DUSP2/3/4/6/7) and ERK transcriptional programs (e.g., JUNB, ATF3, FOSL, ID1, KLF2). Although many of the previously described negative feedback pathways governing EGFR signaling are preserved in cancers, when expression of negative feedback regulators was compared between normal and cancer cells, several were found to be underexpressed in tumors. These data helped confirm the continued existence of negative feedback modules in transformed cells while also suggesting that loss of some of the negative feedback components might contribute to tumor progression.

**Persistence of Negative Feedback in Tumors**

In tumors characterized by the presence of a mutationally activated oncprotein in the signaling pathway, one might expect the persistently elevated signaling to induce persistently high levels of negative feedback. Alternatively, the expectation might be that the persistently elevated signaling was enabled by the loss or suppression of negative feedback. Pratilas and colleagues (11) evaluated ERK-dependent transcriptional output and feedback signaling in tumor cells in which ERK signaling is driven by mutant BRAF and in tumor cells in which ERK is driven by upstream receptors like EGFR or HER2. Comparison of the tumors in the steady state and under conditions of MEK inhibition revealed that a negative feedback program (DUSPs, Sproutys) is expressed at a considerably higher level in the BRAF-mutant tumors. The observation is in line with the first expectation, an activating oncprotein in the signaling pathway leads to persistently elevated feedback. However, the presence of high-level feedback in these tumors raises a conundrum: how is the mutant oncprotein able to signal and generate oncogenic output in the face of elevated and persistent negative feedback? The findings in the article on relative MEK and ERK phosphorylation (11) as well as more recent studies suggest that, at least in the case of mutant BRAF in melanoma, the oncprotein is insensitive to the feedback. The BRAFmutant can signal independently of the constraints imposed by negative feedback regulating RTKs and RAS (12). This of course does not rule out the possibility that individual components of the entire negative feedback program are lost or modulated during transformation with mutant BRAF as well, but much of the feedback program is evidently preserved. Although in the case of mutant BRAF melanoma, insensitivity to the feedback appears to be critical to oncogenic signaling, in other tumor types, downregulation of the feedback or additional mutational hits to bypass the feedback may be essential. Indeed, as the cancer genome is studied with greater breadth and depth, concurrent mutational lesions (e.g., loss of PTEN and activating PIK3CA mutations in uterine cancer) within an individual growth factor signaling pathway are being increasingly found, and one suggestion is that these lesions may arise in response to the negative feedback loops to enhance pathway output. In general, the negative feedback may be one of the major selection pressures for the specific type(s) of oncogenic hits that arise in a given tumor.

**Relief of Feedback Uncovered by mTORC1 Inhibitors**

The concept that oncproteins induce high levels of feedback inhibition of the signaling network has important implications for targeted therapy. Tumor cells have been said to be “addicted” to driver oncproteins. Indeed, drugs that inhibit oncprotein-activated pathways have been aggressively developed as therapeutics and some of these have remarkable clinical effects. This oncprotein dependence may be the result of the feedback inhibition of important parallel and upstream pathways that cause the cell to become hyperdependent on the oncprotein alone. Inhibition of oncprotein signaling by these drugs not only downregulates the pathway, but also relieves feedback inhibition of other pathways in the network. The consequences of such loss of negative feedback have been most clearly described in the case of drugs targeting the phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR pathway (Fig. 2). It has been previously established in normal cells that activation of the insulin-like growth factor (IGF)/insulin signaling is regulated and limited by feedback inhibition of the expression of insulin receptor substrates (IRS1/2). This is mediated by activation of the PI3K/AKT/mTOR pathway. mTOR phosphorylates and activates S6K1, which
phosphorylates the IRS proteins and both induces their degradation and reduces their interaction with the IGF1R and insulin receptors. This serves to inhibit and self-limit IGF1R and insulin signaling (13).

The PI3K/AKT pathway is constitutively activated in many human tumors. This suggests that S6K-dependent feedback inhibition of signaling might be an important characteristic of these tumors. Rapamycin is an inhibitor of the mTORC1 complex of mTOR and has been tested as an antitumor drug that would inhibit PI3K/AKT/mTOR signaling. Several groups found, however, that rapamycin relieved S6K-dependent feedback and activated AKT in tumor cell lines and in human tumors (14–16). As the action of the drug led to potent and prolonged inhibition of S6K, IRS1 was stabilized and this was associated with an induction of PI3K and AKT kinase activity. Thus, relief of the negative feedback caused activation of a segment of the pathway the drug was meant to inhibit. This specific finding of AKT induction by rapamycin was further confirmed in patients in a neoadjuvant trial of rapamycin in PTEN-deficient glioblastoma in which upregulation in P-AKT by immunohistochemistry was observed in 7 of 10 patients and correlated with a shorter time to progression after surgery (17). With more comprehensive profiling of tumors, additional mechanisms of negative feedback regulation of mTOR signaling are now being identified. For instance, it was recently shown that the adaptor protein GRB10 is directly phosphorylated by mTORC1 (18, 19). Phosphorylation stabilizes GRB10 protein thereby enhancing its suppression of PI3K.

So, inhibitors of mTORC1 function to relieve negative feedback in at least two key ways; they result in enhanced stability of IRS1 and diminished stability of GRB10. In both cases, these actions result in enhanced PI3K-AKT activity. Although these are two important mechanisms of mTOR regulation, it appears likely that several other forms of negative feedback regulation of mTOR exist as well. The redundancy with which mTOR is feedback regulated raises the possibility that this phenomenon will occur with many inhibitors of oncoprotein-activated pathways and that relief of feedback could attenuate or prevent the expected therapeutic effects of such drugs.

**Negative Feedback Regulation Is Multifaceted**

Hyperactivation of the mTOR program in cancer is commonly observed in numerous cancers through mutational events such as loss of the PTEN and INPP4B phosphatases, mutational activation of RTKs such as EGFR and HER2, mutational activation of the small G-protein RAS, and mutational activation of the lipid kinase PI3K. A major route of activation of the mTOR kinase involves activation of the PI3K, which generates the second messenger PIP3 (20). Increased levels of PIP3 lead to membrane recruitment and activation of AKT through phosphorylation by PDK1 and mTORC2 on T308 and S473, respectively. Activated AKT then signals to mTORC1 through at least two routes. First, AKT phosphorylates PRAS40, which helps relieve its inhibitory binding to mTORC1. Second, AKT phosphorylates and...
inhibits TSC2 resulting in activation of mTORC1 by the RHEB GTPase negatively regulated by TSC2. Because the lesions activating this pathway in cancer are predominantly upstream of AKT, direct therapeutic targeting of AKT was envisioned as an approach to block pathway activation while avoiding the consequences of loss of the S6K-IRS1 feedback loop. However, this approach rested on the supposition that the predominant mechanism of negative feedback suppression of the PI3K/AKT/mTOR pathway is mediated by the mTOR-regulated IRS1/GRB10 loops. This did not turn out to be the case. To look for negative feedback modules that might regulate AKT function, a panel of breast tumors was screened for the response of upstream signaling components to AKT pathway inhibition (Fig. 2). Across a wide variety of tumor types, AKT inhibition, but not mTORC1 inhibition, was shown to induce the RNA expression of a set of RTKs (HER3, IGFR1, insulin receptor) with known functions in activating PI3K/AKT signaling (4). This was found to be mediated through the FOXO family of transcription factors, which are direct AKT substrates. As such, an mTOR-independent function of AKT is to exert negative feedback on RTKs. From the different effects of mTORC1 versus AKT inhibition on upstream signaling components comes an additional lens through which we might view targeted therapy of growth factor signaling: part of the action of the drug is to relieve the specific program of negative feedback that normally regulates that molecule. The implications of the drug/target-specific feedback profile vary based on a number of factors (tumor geno-type, lineage, and microenvironment most obviously), but the data suggest it would be insufficient to view the drug as only modulating the oncogenic functions of the target.

**Relief of Feedback Can Reactivate the Inhibited Pathway**

Activation of the AKT kinase has been shown to require a series of steps. Binding of the pleckstrin homology domain with PI3P poises the kinase for proce ssive phosphorylations that occur in the regulatory domain (S473) and catalytic domain (T308). Mutagenesis studies suggest that all of these steps are required for the oncogenic functions of AKT (21). An alternative approach to simultaneously inhibit AKT and mTOR was hypothesized through use of an mTOR kinase inhibitor. Such an inhibitor that binds to the ATP pocket of mTOR would block both mTORC1 complex that regulates S6K1 and 4EBP1 as well as mTORC2 that regulates S473 phosphorylation on AKT. At a minimum, such an inhibitor would be predicted to relieve the negative feedback that regulates the mTORC1 (IRS/GRB10) and the negative feedback that regulates AKT [HER3/IGFR1/insulin receptor (IR)]. Rodrik-Outmezguine and colleagues (22) analyzed the impact of mTOR kinase inhibition and found that indeed the effect of the mTOR kinase inhibitor was to activate upstream PI3K/RTK signaling among other components yet to be fully elucidated. The activation of PI3K through adaptors and RTKs did not alter the ability of the inhibitor to block mTORC2 phosphorylation of S473 on AKT. The surprising finding was that under these conditions of hyperactivated upstream signaling, T308 on AKT was phosphorylated independently of S473 and led to an activated AKT that could resume its oncogenic functions. Inhibition of this S473-inhibited/T308 phosphorylated AKT species could be achieved through inhibitors of the induced RTKs or of the pleckstrin homology domain of AKT and this could durably inhibit AKT’s oncogenic functions. These findings illustrate an important concept about the consequence of negative feedback inhibition, that hyperactivated signals can reactivate the signaling pathway despite continued presence and action of the inhibitor. In this case, the enzymatic function of AKT could be decoupled from its normal regulatory constraints. The loss of negative feedback becomes a tool the network uses to adapt to the pressure of the drug and generate a new steady state that preserves the essential output of the network.

**Relief of Feedback Can Activate Parallel Growth Factor Pathways**

The eukaryotic cell possesses a series of growth factor signaling cascades that it uses to respond to extracellular cues. In many cases, modules such as RAS/RAF/MEK/ERK or PI3K/AKT/mTOR can be adapted onto the same receptor complex through adaptor proteins enabling multiple pathways to be activated by a single growth factor. For instance, heterodimers of the ERBB family can activate the PI3K/AKT cascade directly through sites on HER3 or adaptors such as GRB2 while also directly activating the RAS/RAF/MEK/ERK cascade through sites on EGFR/HER2/HER4 or adaptors such as SHC. Indeed, oncogenic activation of EGFR or HER2 is associated with hyperactivated signaling through both the ERK and AKT pathways. Similarly, activated RAS can activate several signaling modules important for transformed phenotypes including the RAF/MEK/ERK, PI3K/AKT/mTOR, and RAL/CDC42 pathways. Because these upstream effectors can simultaneously activate multiple pathways that may promote tumor growth, conditions that promote loss of negative feedback and activate the upstream components will activate multiple growth factor signaling modules. For instance, Carracedo and colleagues (23) demonstrated that inhibition of mTORC1 with rapamycin not only activated PI3K-AKT signaling, but also induced ERK phosphorylation in cell lines and tumor biopsies from patients treated with the drug. This activation of ERK was demonstrated to be PI3K-dependent and associated with upregulation of CRAF. The specific mechanism of upstream activation was not identified in this analysis but demonstrated the point that persistent inhibition of one pathway could feedback upregulate signaling through another pathway and this could limit the antitumor benefit of the drug. Serra and colleagues (24) demonstrated that inhibition of PI3K/AKT/mTOR signaling could induce the activity and expression of HER family receptors through some of the aforementioned mechanisms of RTK feedback regulation and this resulted in activation of ERK signaling. In this case, simultaneous inhibition of HER kinases blocked the induction in ERK phosphorylation. Although much of the early work on such signaling crosstalk has focused on the canonical PI3K/AKT/mTOR and RAS/RAF/MEK/ERK modules, other signaling modules (e.g., JAK/STAT) have been described to be interconnected and are predicted to be
involved. The precise outputs that these pathways can produce under conditions of potent inhibition of one pathway are unknown. In the case of the AKT and ERK pathways, several key mediators of the transformed phenotype are co-regulated by these pathways and the activity of both may be necessary for output. For instance, in tumors with RAS and PIK3CA mutations, downregulation of both AKT and ERK is necessary to fully recruit the 4EBP1 suppressor to the elf4e mRNA cap complex to block cap-dependent translation (25). In breast tumors with EGFR overexpression and PTEN loss, both ERK and AKT signaling are activated and inhibition of both pathways is necessary for dephosphorylation and activation of the proapoptotic BH3-containing protein, BAD (26). Although these models for dual pathway regulation of tumorigenic functions may not be true for all tumor types, they imply another tumor escape mechanism in which upregulation of crosstalk as a consequence of loss of negative feedback engages these mediators and prevents the antitumor action of the drug.

Relief of Feedback Activating Hormone Signaling Pathways

Growth factor signaling pathways not only have well-established roles collaborating with other polypeptide growth factor signaling pathways, but they also interface with non-polypeptide growth factor signaling pathways such as hormone receptor signals. Cooperative roles for the AKT and ERK pathways with estrogen and androgen receptor (AR) signaling in breast and prostate cancer have been well established. Recent work has highlighted another potential implication for loss of negative feedback with AR signaling. Carver and colleagues (27) used fine transcriptome analyses of prostate cancer to identify crosstalk pathways between AR and PI3K/AKT signaling. In this work, they define “reciprocal feedback” wherein loss of negative feedback is identified under conditions of either androgen deprivation or PI3K inhibition and results in activation of the reciprocal pathway (Fig. 3). So, inhibition of PI3K/AKT signaling drives androgen signaling in part through upregulation of ERBB kinase expression and activity. Meanwhile, androgen deprivation induces PI3K/AKT activity through repression of the PHLPP phosphatase that regulates AKT. The mechanistic understanding of how these discrete signaling pathways can be linked raises a theory about how such negative feedback might play a role in the evolution of tumors. Mutational activation of one signaling network will repress lateral signaling pathways through induction of negative feedback programs. For instance, loss of PTEN should suppress AR signaling in part through negative feedback on RTKs. The pressure of this relative androgen deprivation for key androgen outputs may help select for mutational events that drive up AR expression or androgen production. The tumor cell with coexistent mutations is then buffered against scarcity of signals from either pathway. Periods of relative androgen deprivation are compensated by hyperactivation of PI3K/AKT signaling through further loss of PHLPP. Therapeutic efforts at targeting such mutationally mature tumors with monotherapies will similarly drive the cell to dependence on the other through hyperactivation from loss of negative feedback. To the degree this logic holds, rational combinations of therapies must target both the pathway and the loss of negative feedback signal to achieve durable antitumor benefits.

Antitumor Effects of Targeting Relief of Negative Feedback

A key prediction of the hypothesis that loss of negative feedback diminishes the antitumor benefit of targeted therapy is that combinations that can successfully target the loss of negative feedback signal should add meaningful benefit. In a variety of laboratory models, this has proven to be the case, although it has been experimentally difficult to prove that the loss of negative feedback signal was the sole reason. Sergina and colleagues (28) defined how HER2 inhibition with the HER1/2 kinase inhibitor lapatinib led to loss of negative feedback on HER3 and this mediated resistance to the inhibitor. Knocking down the induced HER3 indeed augmented the apoptotic response, but was this through

![Figure 3](image.png)

Figure 3. Reciprocal feedback regulation of PI3K/AKT and AR signaling. A, a model depicting crosstalk between the PI3K/AKT pathway and the AR signaling pathway with each pathway negatively regulating the other. B, the consequence of inhibiting AR signaling with downregulation of AR causing lower levels of FKBP5 and thus impairing the function of the AKT phosphatase PHLPP. The result is that AR inhibition causes an upregulation in AKT activity. C, the consequence of inhibiting PI3K/AKT signaling with downregulation of AKT causing an induction of RTKs such as HER3 and thus causing an induction of AR signaling.
blockade of the induced HER3 or simply superior HER2/HER3 inhibition in the first place? In a similar vein, our group used a schedule of HER1/2 inhibitor to block the feedback signal induced by AKT inhibition and found this to clearly improve the antitumor effects beyond what either inhibitor alone achieved (4). The studies defining upregulation of AKT or ERK in response to mTORC inhibition also demonstrated the added antitumor benefit of blocking ERK with a MEK inhibitor or AKT with a PI3K inhibitor. However, such experiments cannot exclude the possibility that the benefits arise from inhibiting more pathways or more potent inhibition of the pathway upfront. In all cases, the experiments published to date have been highly consistent with the concept that strategies that incorporate blocking the loss of negative feedback are superior in depth and duration of antitumor benefit; nevertheless, a definitive set of experiments to selectively isolate the impact of loss of negative feedback remains to be demonstrated.

**Clinical Efforts at Targeting Relief of Negative Feedback**

Given the possible synthetic lethal effects of targeting the oncogenic pathway and one of the loss of feedback signals, several groups are now testing combinations designed to block loss of feedback signals. As some of the initial findings of loss of negative feedback were identified with rapamycin, several trials have examined combinations with this compound. In *HER2*-amplified breast cancer, the rapamycin-induced activation of AKT is HER2 dependent (unpublished data). Moreover, one of the primary modes of resistance to HER2-targeted therapies has been mutational activation in PI3K or loss of PTEN, suggesting an epistatic role for mTOR inhibitors. As such, combinations of rapamycin with HER2-targeted therapy represent a rational approach. Morrow and colleagues (29) combined everolimus with the HER2 antibody trastuzumab and observed a 15% response rate in trastuzumab-refractory patients, which is higher than either single agent might be predicted in this setting. This study can only incompletely model loss of negative feedback given that trastuzumab is a weak inhibitor of HER2 signaling, particularly in trastuzumab-refractory disease, and so the drug may not have been sufficient to block the rapamycin feedback. Our group has recently reported on a phase I/II study of trastuzumab-refractory *HER2*+ breast cancers combining temsirolimus with an irreversible HER1/2 inhibitor, neratinib. Although patient numbers are small, 9 of 12 patients treated at the maximally tolerated dose had a partial response with two of these responses lasting for more than 16 months (30). Such activity has not been without some toxicity and raises the concern that these negative feedback pathways represent mechanisms that normal cells use to avoid death from targeted therapy. Although neither study has reported untoward or magnified toxicities beyond what has been seen for the single agents, this concern may represent an obstacle to efforts at such combinations. Two understandings needed in this regard are a fuller description of which negative feedback pathways are cancer cell-specific for survival as well as knowledge of the dose and schedule of the combinations that maximize the therapeutic index.

**Future Directions in Targeting Adaptive Resistance**

Overall, the findings from both the laboratory and the clinic implicate negative feedback as an important and targetable mechanism of drug resistance. At a minimum there are four areas in which this concept needs to be advanced to move beyond pioneering examples. First, a more comprehensive view of the feedback program regulating a given oncogene-driven network is needed. Studies examining the effects of drugging the PI3K/AKT/mTOR and RAS/RAF/MEK pathways have revealed dense layers of negative feedback rather than singular feedback loops. Some of these pathways are unique to specific cell lineages, whereas others are unique to specific tumor genotypes. The powerful technologies for global assessment of gene expression/ modification, protein expression/modification, and so on, need to be used to identify characteristic responses to selective inhibitors of these signaling networks. The ability to mine such data will depend heavily on the use of inhibitors that are highly selective for their target and cancer models that effectively mimic the genetic complexity of the diseases being studied. As common feedback modules are identified, a second key area for research on negative feedback in cancer is to define the relevance of the individual feedback programs for adaptive phenotypes. Based on the findings to date, it is very likely that numerous negative feedback loops will be found for a given oncogene. It may not be practical or desirable to block all of the feedback programs induced by the drug. Indeed, some of these feedback loops may be used by normal cells to survive a drug and avert toxicity. Nevertheless, cancer cells may have an Achilles’ heel in terms of specific feedback loops that are essential for survival. Apart from inducing cell death, some of the adaptive resistance phenotypes are likely to engender other changes in cell fate. For instance, drug-induced feedback may enable a metastatic or quiescence program rather than activating continued proliferation. Careful analysis of the cell biology of adaptive programs will be essential to identifying combination therapeutic strategies that effectively translate to patients. As rational combination strategies to target the oncogene and the negative feedback program are being identified, it will be essential to simultaneously identify biomarkers that predict which tumor types will most benefit. To the degree that mTORC1 inhibition induces AKT and ERK, in which patients should we add a MEK inhibitor and in which patients should we add an AKT inhibitor? The third major area of understanding needed to advance effective translation of this concept will be development of robust predictors of response for such combinations. In this regard, it will be necessary for studies performed on feedback responses to extend beyond one or two cell lines and identify genotype, cell of origin, chromatin state, or other marks to ultimately guide patient selection. Finally, although much of this work will be most realistically achieved using cancer cell lines, mouse models, and patient-derived xenografts, there remain reasons to be concerned that these will not fully capture the clinical feedback response. A critical component of the feedback response relies on upstream components like receptors that are strongly influenced by the microenvironment and ligand milieu in...
which they are found. Moreover, the pharmacodynamics of drug inhibition in the tumor are not well modeled outside the host as a result of specific circumstances such as drug metabolism and tumor vasculature. Despite the hurdles involved, there is still no effective substitute for the gold standard of the patient tumor biopsy. As drugs are developed in the clinic, carefully planned tumor biopsies before therapy and while on therapy will yield vital information toward understanding and validating the feedback responses. The oncprotein-driven signaling pathway can be more realistically envisioned as a web with multiple interconnected inputs. Pressuring the web at a singular point will move some aspects of it in a specified direction, but other significant regions will run counter to this, in part as a result of negative feedback. Synthetic lethality may be an achievable outcome by pressuring the network at both a key node and the major negative feedback signal that is relieved in response. Exploiting such vulnerabilities may greatly improve the chances of therapeutic success. Avant-garde trial designs incorporating tumor biopsies to identify adaptive responses and drug them in patient-specific ways may ultimately represent the idealized way forward but will necessarily involve the commitment of investigators, philanthropists, and pharmaceutical companies to understanding and modulating these networks in all their complexity and heterogeneity.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: S. Chandarlapaty
Analysis and interpretation of data: S. Chandarlapaty
Writing, review, and/or revision of the manuscript: S. Chandarlapaty

Acknowledgments

I thank Neal Rosen, Poulikos Poulakakos, Marie Will, Brett Carver, Charles Sawyers, Maurizio Scudiero, and José Baselga for their insight and helpful discussions and Eric Joseph for his comments and assistance with illustrations.

Grant Support

This work is supported by NIH Mentored Clinical Scientist Award K08-CA134833 and the Geoffrey Beene Cancer Center.

Received January 23, 2012; revised March 1, 2012; accepted March 2, 2012; published OnlineFirst March 22, 2012.

REFERENCES

Adaptive Resistance to Targeted Therapy in Cancer


Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer

Sarat Chandarlapaty